Tags : ADX-2191

Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative

Tuba Khan September 24, 2019

Shots: The US FDA has granted FT designation to ADX-2191 for the prevention of proliferative vitreoretinopathy and provides it eligibility for Priority Review and rolling NDA submission The FDA’s FT […]readmore

Tags : ADX-2191

Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ADX-2191

﻿Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative